Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo ANDA Approval Brings New Options To Generic Mucinex DM Maximum Strength Portfolio

Executive Summary

Perrigo's first OTC drug approved in 2018 is extended-relief guaifenesin 1,200 mg and dextromethorphan 60 mg tablets, planned for launch under its own store brand, Goodsense, as well as distribution for retailer and private label brands. It already distributes the product for store and private label brands through an agreement with Teva.

You may also be interested in...



Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains

Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.

Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains

Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.

Reckitt Boosts 2018 Guidance A Year After Gaining China Platform With MJN

Reckitt reports infant formula sales in China drove a 9% pro-forma increase in its child nutrition segment in second quarter, prompting a revenue forecast on the higher end of a 2%-3% projection. Firm says new infant formula and VMS products, including an improved Move Free formula, will continue to strengthen the sector.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel